EBOS Group Ltd

EBOS Group Ltd

Health CareMedical Equipment and Services
  • Price (AUD)38.42
  • Today's Change0.56 / 1.48%
  • Shares traded15.99k
  • 1 Year change+10.09%
  • Beta--
Data delayed at least 20 minutes, as of Dec 01 2022 04:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

EBOS Group Limited is an Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is also an Australasian animal care brand owner, product marketer, and distributor. Its segments include Healthcare, Animal Care and Corporate. The Healthcare segment incorporates the sale of healthcare products in a range of sectors, such as own brands, retail healthcare, medical devices, capital equipment, pharmacy services, and wholesale activities. The Animal Care segment incorporates the sale of animal care products in a range of sectors, own brands, retail, and wholesale activities. Its Community Pharmacy business includes Symbion, Endeavour Consumer Health, ProPharma, DoseAid, TerryWhite Chemmart, and Pharmacy Wholesalers Russells, among others. Its Contract Logistics business includes Healthcare Logistics and Healthcare Logistics Clinical Trials. Its Institutional Healthcare includes Clinect, Cryomed Aesthetics and Onelink, among others.

  • Revenue in NZD (TTM)11.58bn
  • Net income in NZD218.56m
  • Incorporated1922
  • Employees3.99k
  • Location
    EBOS Group Ltd108 Wrights RoadCHRISTCHURCH 8024New ZealandNZL
  • Phone+64 33380999
  • Fax+64 33395090
  • Websitehttp://www.ebosgroup.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.